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Nanomaterials are used for various biomedical applications because they are often more effective than conventional
materials. Recently, however, it has become clear that the protein corona that forms on the surface of nanomaterials
when they make contact with biological fluids, such as blood, influences the pharmacokinetics and biological
responses induced by the nanomaterials. Therefore, when evaluating nanomaterial safety and efficacy, it is
important to analyze the interaction between nanomaterials and proteins in biological fluids and to evaluate
the effects of the protein corona. Here, we evaluated the interaction of silica nanoparticles, a commonly used
nanomaterial, with the human blood proteins albumin, transferrin, fibrinogen, and IgG. Sodium dodecyl
sulfate-polyacrylamide gel electrophoresis analysis showed that the amount of albumin, transferrin, and IgG
binding to the silica particles increased as the particle size decreased under conditions where the silica particle
mass remained the same. However, under conditions in which the specific surface area remained constant, there were
no differences in the binding of human plasma proteins to the silica particles tested, suggesting that the binding
of silica particles with human plasma proteins is dependent on the specific surface area of the silica particles.
Furthermore, the amount of albumin, transferrin, and IgG binding to silica nanoparticles with a diameter of
70 nm (nSP70) and a functional amino group was lower than that with unmodified nSP70, although there
was no difference in the binding between nSP70 with the surface modification of a carboxyl functional group
and nSP70. These results suggest that the characteristics of nanomaterials are important for binding with human
blood proteins; this information may contribute to the development of safe and effective nanomaterials.
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The development and use of materials at the nanometer
scale already have multiple applications in various fields,
including the food and cosmetics industries; such nano-
materials have thus become indispensable in our lives
[1,2]. Silica nanoparticles have been widely used in many
consumer products because of their useful properties,
including relatively low production costs, easy separ-
ation, and ease of modification of their surface proper-
ties. Accordingly, they have attracted the attention of the* Correspondence: yasuo@phs.osaka-u.ac.jp; ytsutsumi@phs.osaka-u.ac.jp
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and diagnostic systems [3]. However, because nanomaterials
possess novel properties that are different from conventional
materials, concerns about their potential unanticipated
effects have been raised. We previously found that sil-
ica nanoparticles with a diameter of ≤100 nm could cause
pregnancy complications [4] or consumptive coagulopathy
in mice after systemic exposure [5] compared with silica
particles with a diameter of >100 nm. We also demon-
strated that the surface-modified silica nanoparticles were
unlikely to induce undesired inflammatory responses
in vitro and in vivo, suggesting that it might be possible to
decrease the adverse biological effects of nanomaterials
and enhance nanomaterial safety by modifying their sur-
face properties [6,7].
Nanomaterial-mediated biological effects are related to
physical characteristics such as particle size and theOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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terials interact with proteins, a protein layer forms around
the nanomaterials, referred to as the protein corona,
which is dependent on the physical characteristics of the
nanomaterial [8,9]. Many studies have shown that this
protein corona plays a role in the biological effects in-
duced by the nanomaterial and in the in vivo and in vitro
kinetics of the nanomaterial. For example, Jiang et al.
demonstrated that the uptake of FePt nanoparticles
by HeLa cells is suppressed by the adsorption of hu-
man transferrin compared with that of the bare nano-
particles [10]. Similarly, the work of Ge et al. suggests
that the binding of blood proteins to carbon nanotubes re-
duces those nanotubes’ cytotoxicity [11]. Therefore, it is
important to understand how nanomaterials interact
with proteins to clarify both the biodistribution and
safety of such nanomaterials. Although proteomics stud-
ies have comprehensively identified the blood proteins
that make direct contact with nanomaterials, detailed
analyses of the binding to individual blood proteins are
incomplete lacking. To fully realize the potential of
the protein corona, it is essential to understand and
quantify the effects of individual proteins on the char-
acteristics of nanomaterials. Furthermore, analyses of
the amount of binding of each individual human plasma
protein to nanomaterials with various properties would
be invaluable in developing the safety profile of such
nanomaterials.
In this study, we assess the differences in the interac-
tions between major blood proteins and silica nanoparti-
cles by changing nanomaterial characteristics such as
size, specific surface area, and surface modification.Methods
Materials
Human albumin (molecular weight 66 kDa), human fi-
brinogen (molecular weight 340 kDa), and human trans-
ferrin (molecular weight 78 kDa) were purchased from
Wako (Osaka, Japan). Human immunoglobulin G (IgG)
(molecular weight 146 kDa) was purchased from Oriental
Yeast Co. Ltd. (Tokyo, Japan) and human α1-acid glyco-
protein (AGP) (molecular weight 44.1 kDa) was purchased
from Sigma-Aldrich (Saint Louis, MO, USA).Silica particles
Silica particles were purchased from Micromod Partikel-
technologie (Rostock/Warnemünde, Germany). Silica par-
ticles with diameters of 70, 100, 300, and 1,000 nm (nSP70,
nSP100, nSP300, and mSP1000, respectively) and nSP70
with the surface modification of an added amino group
(nSP70-N) or an added carboxyl group (nSP70-C) were
used in this study. These particles were sonicated for
5 min and vortexed for 1 min prior to use.Recovery of silica particles
Suspensions of silica particles (200 μL) were centrifuged
at 21,500 × g for 20 min at 4°C. The pellets were washed
three times with 500 μL of phosphate buffered saline
(PBS) and then dissolved in 200 μL of 5% HNO3 (Nacalai
Tesque, Kyoto, Japan). The solutions (100 μL) were then
transferred to centrifugation tubes and 5 mL of Milli-Q
water (Millipore, Billerica, MA, USA) was added to each
tube. The silicon content of the samples was analyzed by
using inductively coupled plasma mass spectrometry
(ICP-MS) (Agilent Technologies, Santa Clara, CA, USA).
The recovery of the silica particles was calculated as the
ratio of the silicon signal (cps) of the centrifuged samples
to that of the uncentrifuged samples.
Gel electrophoresis
Each protein solution (200 μL), adjusted with PBS to ob-
tain concentrations commonly found in human blood
(albumin, 40 mg/mL; fibrinogen, 2 mg/mL; transferrin,
2 mg/mL; IgG, 10 mg/mL; and AGP, 0.5 mg/mL), was
mixed with nSP70, nSP100, nSP300, mSP1000, nSP70-C,
or nSP70-N (25 mg/mL) at 1:1 (v/v). To assess the effect
of the specific surface area, each protein solution was
mixed with nSP70 (1.08 × 106 mm2/mL), nSP100 (7.54 ×
105 particles/mL), nSP300 (2.54 × 105 mm2/mL), or
mSP1000 (7.54 × 104 particles/mL) at 1.75, 2.5, 7.41, and
25 mg/mL, respectively, which is about 1.5 × 104 mm2 of
specific surface area for each particle. The mixtures were
then vortexed and incubated at 37°C for 1 h with constant
rotating. The proteins bound to silica particles were sepa-
rated by centrifugation at 21,500 × g for 20 min at 4°C.
The pellets were washed three times with 500 μL of PBS
to remove the unbound proteins. Proteins bound to the
silica particles were suspended in 10% sodium dodecyl sul-
fate (SDS) buffer (sample solution). Then, the sample so-
lution and Laemmli sample buffer (Bio-Rad Laboratories,
Hercules, CA, USA) were mixed in equal amounts (mix-
ture solution) and boiled for 5 min at 95°C. The IgG
samples were diluted tenfold before being mixed with
the sample buffer because their concentrations were too
high to analyze the bands clearly. Each sample was sepa-
rated by SDS polyacrylamide gel electrophoresis (PAGE)
(ATTO, Tokyo, Japan). For the analysis of albumin, trans-
ferrin, and IgG, 10% to 20% e-PAGEL was used; for
fibrinogen, 5% e-PAGEL was used. Electrophoresis was
performed at 15 mA/gel for 10 min (stacking), followed by
separation (600 V, 40 mA/gel) for approximately 45 min.
After the electrophoresis, the gel was stained by Coomassie
brilliant blue (CBB) staining, and the protein bands were
quantified with the ImageJ software (http://rsb.info.nih.
gov/ij/). The protein content of each band was estimated
from its optical density compared with that of each stand-
ard solution. As standard solutions, the following protein
concentrations were prepared: albumin at 0.08, 0.16, 0.4,
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AGP at 0.05, 0.1, 0.25, and 0.5 mg/mL; IgG at 0.1, 0.2, 0.5,
and 1.0 mg/mL; and fibrinogen at 0.2, 0.4, 1.0, and 2.0 mg/
mL. The degree of binding was calculated by taking the the-
oretical concentrations calculated from the proteins added
to the silica particles originally as 100%. Values less than
the detection limit of the standard curve for each protein
were recorded as 0%, even if bands were slightly detectable.
Statistical analyses
All results are expressed as means ± SD. Differences were
compared by means of Tukey’s multiple comparison test.
Results
Recovery of silica particles after centrifugation
In this study, we used silica particles with diameters of
70 nm (nSP70), 100 nm (nSP100), 300 nm (nSP300), and
1,000 nm (mSP1000), and nSP70 surface-modified with a
carboxy group (nSP70-C) or an amino group (nSP70-N).
The physical characteristics of these particles were assessed
in previous studies [4,12]. Transmission electron micros-
copy analysis showed that they were smooth-surfaced
spheres. Dynamic light scattering analysis revealed that the
hydrodynamic diameters were 76, 106, 264, and 1136 nm
for nSP70, nSP100, nSP300, and mSP1000 in PBS (pH7.4),
respectively, and that the zeta potential of each par-
ticle was −19.5, −24.3, −25.8, and −33.2 mV, respectively.
In addition, we previously reported that the mean second-
ary particle size of nSP70-C and nSP70-N was 69.6 and
71.8 nm, respectively, and that the zeta potentials
were −76.3 and −29.0 mV, respectively. The size dis-
tribution spectrum of each set of silica particles showed a
single peak, and the measured hydrodynamic diameter
corresponded almost precisely to the primary particle size
of each set of silica particles. These results indicate that
the silica particles used in this study were well-dispersed
in solution.
First, we wanted to evaluate the binding of silica parti-
cles with the major blood proteins after they were mixed
and then centrifuged. Therefore, it was essential to assess
how much of each silica particle was precipitated after
centrifugation. We analyzed the recovery of each silica
particle after centrifugation by using ICP-MS. ICP-MS
analysis showed that the percentage recovery of nSP70,
nSP70-N, nSP70-C, nSP100, nSP300, and mSP1000 was
71.0, 78.5, 71.5, 80.9, 82.6, and 77.2, respectively. These re-
sults show that the amounts of each silica particle recov-
ered were similar, indicating that it would be appropriate
to directly compare the degree of binding of each silica
particle to the proteins.
Effects of particle size on binding to proteins
Next, we evaluated whether the differences in the size of
the silica particles affected their binding to albumin,transferrin, fibrinogen, and IgG. We selected these pro-
teins because these have high concentrations in human
blood [13] and because the frequency of contact in the
body is considered to be high. In addition, it was re-
ported that these proteins were identified in protein cor-
ona on silica nanoparticles with human plasma [14,15].
SDS-PAGE analysis showed that there was no inter-
action between the silica particles and AGP (data not
shown). For albumin (Figure 1A) and IgG (Figure 1C),
the binding was dependent on the diameter of the silica
particles. For transferrin, we found that nSP300 and
mSP1000 did not bind (Figure 1B). In addition, the de-
gree of binding of mSP1000 with fibrinogen was signifi-
cantly lower than that of the other particles (Figure 1D).
These results indicate that the binding of silica particles
to albumin and IgG appears to increase as the particle
size decreases. The degree of nSP70 binding was greatest
with fibrinogen and smallest with albumin among these
four proteins tested.
We also evaluated the effect of the specific surface
area of the silica particles on binding to human plasma
proteins. The specific surface areas of each particle were
matched with that of 25 mg/mL of mSP1000 (about
1.5 × 104 mm2), because mSP1000 was the largest particle
in this study. The results showed that there was no signifi-
cant difference in binding with each protein among each
size of silica particle tested (Figure 2A,B,C,D), suggesting
that the binding of silica particles to human plasma pro-
teins is dependent on the specific surface area of the silica
particles.
Effects of particle surface charge on binding to proteins
The physical properties of nanomaterials, including sur-
face properties and morphology, are important factors in
the biological responses to these materials. We previ-
ously demonstrated that nSP70 surface-modified with a
carboxyl or amino group might induce abnormal activa-
tion of the coagulation cascade to a lesser extent than
does unmodified nSP70 [12] and that differences in the
properties of surface-modified silica nanoparticles directly
affect the extent to which these particles interact with
blood proteins, such as coagulation factor XII (unpub-
lished data). Here, we assessed how surface modification
affected the protein binding with silica nanoparticles. The
surface modification of adding an amino group weakened
the binding of nSP70 to albumin (Figure 3A), transferrin
(Figure 3B), and IgG (Figure 3C), although the surface
modification of adding the carboxyl-group made no no-
ticeable difference to the binding of nSP70 to albumin and
IgG. Similarly, there was no difference in fibrinogen bind-
ing among these three silica nanoparticles, suggesting that
the physical properties associated with nanoparticle inter-
action with proteins are dependent on the kind of protein
involved.
Figure 1 Effects of silica particle size on binding to human plasma proteins. Each protein solution was mixed with SP70, nSP100, nSP300, or
mSP1000 (25 mg/mL). After centrifugation, each sample was separated by SDS-PAGE. The gel was stained by CBB staining, and the protein bands
of albumin (A), transferrin (B), IgG (C), and fibrinogen (D) were quantified with the ImageJ software. The protein content of each band was
estimated from its optical density compared with the optical density of each standard solution. Data are presented as the mean ± SD;
n = 4; **P < 0.01 vs. nSP70-treated group; *P < 0.05 vs. nSP70-treated group; N.D., not detected.
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Here, we assessed the effect of nanoparticle size on bind-
ing to proteins. We found that the binding of silica parti-
cles to albumin, transferrin, and IgG appears to increase
as the particle size decreased (Figure 1A,B,C). However,
we found no significant difference in binding to these pro-
teins when the specific surface area of the different silica
particles was the same (Figure 2A,B,C). The larger specific
surface area of nSP70 relative to that of nSP300 and
mSP1000 may have allowed the smaller particles to inter-
act with biomolecules such as proteins. These results indi-
cate that specific surface area plays a role in determining
silica nanoparticle-protein interactions. How specificsurface area influences nanoparticle binding to plasma
proteins is poorly understood [16]. Several studies have
shown that biological responses to nanomaterials could
depend on specific surface area rather than on the mass of
the particle [17]. Therefore, biological responses should
be assessed in terms of the nanomaterial specific sur-
face area-protein interaction.
The surface charge of the nanomaterials affects the com-
position of the protein corona. We demonstrated that
the surface modification of adding an amino group to
nSP70 weakens the binding of nSP70 to albumin, trans-
ferrin, and IgG, although there were no significant differ-
ences between the binding of nSP70 and that of nSP70
Figure 2 Effects of the specific surface area of silica particles on binding to human plasma proteins. Each protein solution was mixed
with SP70, nSP100, nSP300, or mSP1000 at 1.75, 2.5, 7.41, and 25 mg/mL, respectively (i.e., approximately 1.5 × 104 mm2 of specific surface area).
After centrifugation, each sample was separated by SDS-PAGE. The gel was stained by CBB staining, and the protein bands of albumin (A), transferrin
(B), IgG (C), and fibrinogen (D) were quantified with the ImageJ software. The protein content of each band was estimated from its optical
density compared with the optical density of each standard solution. Data are presented as the mean ± SD; n = 3; **P < 0.01 vs. nSP70-treated
group; *P < 0.05 vs. nSP70-treated group; N.D., not detected.
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(Figure 3A,B,C). One study showed that polystyrene nano-
particles with a positively charged functional group were
more likely to adsorb to proteins with an isoelectric point
(pI) ≤5.5, whereas polystyrene nanoparticles with a
negatively charged functional group were more likely to
adsorb to proteins with a pI >5.5, and the distinct proteins
appeared to show a preference for different functional
groups [18]. Our results showed that the binding of
nSP70-N with albumin (pI 5.92), transferrin (pI 6.81), and
IgG (pI 6.4 to 6.9) was reduced relative to that of nSP70.
It is conceivable that nSP70-N displayed a positive
charge as −NH3
+ in solution and that it did not show
any preference for proteins with a pI >5.5. However, there
was no significant difference in binding to fibrinogen (pI
5.7) between nSP70 and nSP70-N (Figure 3D). Fibrinogen
binds to a wide variety of nanomaterials because it hasseveral different binding domains that accommodate dif-
ferent nanomaterials [19]. Therefore, to understand the
differences in the interactions between blood proteins and
nanomaterials, it is essential to assess not only the charac-
teristics of the nanomaterials but also the physical proper-
ties of the absorbed proteins such as their molecular
weight, pI, and structure.
According to the technical data sheets posted in Micromod
Partikeltechnologie, the nSP70 in this study became cov-
ered with silanol groups and was modified by the addition
of an amino or a carboxyl group through its spacer struc-
ture. It is difficult to simply compare the difference
between nSP70 and modified-nSP70 in terms of their in-
teractions with proteins, but we believe that a difference
in the binding domain affinities of the respective particles
resulted in the difference in binding between nSP70 and
nSP70-N.
Figure 3 Effects of surface modification of silica particles on binding to human plasma proteins. Each protein solution was mixed with
SP70, nSP70-N, or nSP70-C (25 mg/mL). After centrifugation, each sample was separated by SDS-PAGE. The gel was stained by CBB staining, and
the protein bands of albumin (A), transferrin (B), IgG (C), and fibrinogen (D) were quantified with the ImageJ software. The protein content of
each band was estimated from its optical density compared with the optical density of each standard solution. Data are presented as the
mean ± SD; n = 4; **P < 0.01 vs. nSP70-treated group; *P < 0.05 vs. nSP70-treated group; N.D., not detected.
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important roles in the ultimate fate of these nanomater-
ials in the body and in the subsequent nanomaterial-
induced biological effects [20]. In this study, we showed
that the degree of nSP70 binding to fibrinogen was
greater than that to the other proteins tested (Figure 1A,
B,C,D). The adsorption of opsonins such as fibrinogen
and IgG creates a molecular signature that is recognized
by immune cells and determines the route of particle in-
ternalization. This promotes phagocytosis and removal
of the particles from the systemic circulation by cells of
the mononuclear phagocytic systems [16,21]. Moreover,
the nanoparticle-induced unfolding of fibrinogen has
been shown to promote inflammation via Mac-1 recep-
tor activation [17]. These data and our current results
showing that the binding of nSP70 to fibrinogen was
greater than that to other proteins are consistent with
our previous finding that silica nanoparticles induce
strong inflammatory responses [7]. We believe that this
study on the interactions of nanomaterials with individ-
ual proteins provides essential information for evaluatingthe biological responses to nanomaterials and that it
could lead to the development of safer and more effica-
cious nanomaterials.
Conclusions
Here, we showed that the binding of silica nanoparti-
cles with albumin, transferrin, IgG, and fibrinogen is
dependent on the specific surface area, not the size of
the silica nanoparticles. We also showed that the binding
rates of nSP70-N to albumin, transferrin, and IgG were
weaker than that of nSP70 and nSP70-C; however, there
was no difference in fibrinogen binding among nSP70,
nSP70-N, and nSP70-C. We expect that it was connected
for the development and use of safer and more effective
nanomaterials by understanding the interaction between
the nanomaterials and the proteins.
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